| Uses of Curcumin |
||||
| Clinical Trails |
||||
| CurcuminInfo.org |
| Curcumin The Solid Gold |
| For The Benefit of Those who Believe in It. |
| Chemistry |
| Solubility |
| Metabolism |
| Biological Properties |
| Curcuminoid Sources |
| Cancer |
| Cardiovascular |
| Pulmonary |
| Neurological |
| Molecular Targets |
| Evidence Based Medicine |
| EGFR |
| NF-kB |
| STAT3 |
| PPAR-gamma |
| AP-1 |
| Adhesion molecules |
| COX-2 |
| VEGF |
| MMP-9 and iNOS |
| Cyclin D1 |
| Androgen receptors |
| Farnesyl protein |
| Egr-1 |
| JNK |
| Protein kinases |
| HER2/neu |
| Uses of Curcumin |
| Therapeutic potential of curcumin |
| Antioxidant Properties |
| Chemical Composition |
| Chemosenitivity |
| Radiosensitizing effects |
| Radioprotection |
| Natural/Synthetic Analogs |
| Adverse Effects |
| Sources of Curcumin |
| Muscle Regeneration |
| Wound-healing |
| Arthritis |
| Gall-stones |
| Multiple Sclerosis |
| Alzheimer's disease |
| Cataract formation |
| Myocardial toxicity |
| Alcohol-induced liver |
| Drug-induced lung |
| Nephrotoxicity |
| Scarring |
| Inflammatory Bowel |
| Immunosuppresive |
| HIV |
| Stress |
| Endotoxin shock |
| Pancreatitis |
| Cystic fibrosis |
| Metabolism |
Curcumininfo.org Although science has led to remarkable additions to our repertoire of drugs, it is estimated that 80% of the World population cannot afford the current treatment for their diseases. For many modern medicines their benefits are outweighed by their toxic side effects. Thus treatments that are safer, more effective, and cheaper are needed. The mechanisms of action of traditional medicines are shrouded in mystery, even though they have been used for thousand of years: neither the active components nor their molecular targets have been very well identified. Curcumin, a yellow component of turmeric or curry powder, however, is an exception. Almost 2000 papers have been published on the subject. Its mechanism of action can be compared to inhibitors of cyclooxygenase- 2 (Celebrex), HER2 (Herceptin), TNF (Enbrel, Humira, Remicade), EGFR (Erbitux and Iressa), and vascular endothelial cell growth factor (Avastin), all of which have been approved for human use by the FDA. There is one big difference, however: curcumin as a single agent can downregulate every one of these targets, making it more likely to be effective against the targeted disease. Thus curcumin regulates multiple targets (multitargeted therapy) and is inexpensive. Centuries of use as a dietary agent have demonstrated its safety; as an added reassurance, human clinical trials of curcumin have shown it to be safe. For further proof of concept, please visit this website. |